Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.
Looking for a particular Dragonfly Therapeutics, Inc. employee's phone or email?
The Dragonfly Therapeutics, Inc. annual revenue was $8.4 million in 2026.
William Haney is the Co-founder and CEO of Dragonfly Therapeutics and Skyhawk Therapeutics of Dragonfly Therapeutics, Inc..
90 people are employed at Dragonfly Therapeutics, Inc..
Dragonfly Therapeutics, Inc. is based in Waltham, Massachusetts.
The NAICS codes for Dragonfly Therapeutics, Inc. are [54, 54171, 5417, 541714, 541].
The SIC codes for Dragonfly Therapeutics, Inc. are [873, 87].